162 related articles for article (PubMed ID: 22607035)
1. Pyrazolopyridines as inhibitors of the kinase LRRK2: a patent evaluation (WO2011141756).
Deng X; S Gray N
Expert Opin Ther Pat; 2012 Jun; 22(6):709-13. PubMed ID: 22607035
[TBL] [Abstract][Full Text] [Related]
2. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).
Deng X; Choi HG; Buhrlage SJ; Gray NS
Expert Opin Ther Pat; 2012 Dec; 22(12):1415-26. PubMed ID: 23126385
[TBL] [Abstract][Full Text] [Related]
3. Response to Deng et al.'s LRRK2 patent review.
Burdick DJ
Expert Opin Ther Pat; 2013 Feb; 23(2):279. PubMed ID: 23268730
[No Abstract] [Full Text] [Related]
4. Chemical Biology of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors.
Estrada AA; Sweeney ZK
J Med Chem; 2015 Sep; 58(17):6733-46. PubMed ID: 25915084
[TBL] [Abstract][Full Text] [Related]
5. Triazolopyridazine LRRK2 kinase inhibitors.
Franzini M; Ye XM; Adler M; Aubele DL; Garofalo AW; Gauby S; Goldbach E; Probst GD; Quinn KP; Santiago P; Sham HL; Tam D; Truong A; Ren Z
Bioorg Med Chem Lett; 2013 Apr; 23(7):1967-73. PubMed ID: 23454015
[TBL] [Abstract][Full Text] [Related]
6. Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffold.
Galatsis P; Henderson JL; Kormos BL; Han S; Kurumbail RG; Wager TT; Verhoest PR; Noell GS; Chen Y; Needle E; Berger Z; Steyn SJ; Houle C; Hirst WD
Bioorg Med Chem Lett; 2014 Sep; 24(17):4132-40. PubMed ID: 25113930
[TBL] [Abstract][Full Text] [Related]
7. Effect of selective LRRK2 kinase inhibition on nonhuman primate lung.
Fuji RN; Flagella M; Baca M; Baptista MA; Brodbeck J; Chan BK; Fiske BK; Honigberg L; Jubb AM; Katavolos P; Lee DW; Lewin-Koh SC; Lin T; Liu X; Liu S; Lyssikatos JP; O'Mahony J; Reichelt M; Roose-Girma M; Sheng Z; Sherer T; Smith A; Solon M; Sweeney ZK; Tarrant J; Urkowitz A; Warming S; Yaylaoglu M; Zhang S; Zhu H; Estrada AA; Watts RJ
Sci Transl Med; 2015 Feb; 7(273):273ra15. PubMed ID: 25653221
[TBL] [Abstract][Full Text] [Related]
8. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
Kethiri RR; Bakthavatchalam R
Expert Opin Ther Pat; 2014 Jul; 24(7):745-57. PubMed ID: 24918198
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, Docking Study and Kinase Inhibitory Activity of a Number of New Substituted Pyrazolo[3,4-c]pyridines.
Sklepari M; Lougiakis N; Papastathopoulos A; Pouli N; Marakos P; Myrianthopoulos V; Robert T; Bach S; Mikros E; Ruchaud S
Chem Pharm Bull (Tokyo); 2017; 65(1):66-81. PubMed ID: 28049917
[TBL] [Abstract][Full Text] [Related]
10. Indolinone based LRRK2 kinase inhibitors with a key hydrogen bond.
Göring S; Taymans JM; Baekelandt V; Schmidt B
Bioorg Med Chem Lett; 2014 Oct; 24(19):4630-4637. PubMed ID: 25219901
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 4-alkylamino-7-aryl-3-cyanoquinoline LRRK2 kinase inhibitors.
Garofalo AW; Adler M; Aubele DL; Brigham EF; Chian D; Franzini M; Goldbach E; Kwong GT; Motter R; Probst GD; Quinn KP; Ruslim L; Sham HL; Tam D; Tanaka P; Truong AP; Ye XM; Ren Z
Bioorg Med Chem Lett; 2013 Apr; 23(7):1974-7. PubMed ID: 23453068
[TBL] [Abstract][Full Text] [Related]
12. Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2.
Covy JP; Giasson BI
Biochem Biophys Res Commun; 2009 Jan; 378(3):473-7. PubMed ID: 19027715
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation of LRRK2: from kinase to substrate.
Lobbestael E; Baekelandt V; Taymans JM
Biochem Soc Trans; 2012 Oct; 40(5):1102-10. PubMed ID: 22988873
[TBL] [Abstract][Full Text] [Related]
14. Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).
Galatsis P
Expert Opin Ther Pat; 2017 Jun; 27(6):667-676. PubMed ID: 28117607
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of 2-amino-pyrazolopyridines as Polo-like kinase 1 inhibitors.
Fucini RV; Hanan EJ; Romanowski MJ; Elling RA; Lew W; Barr KJ; Zhu J; Yoburn JC; Liu Y; Fahr BT; Fan J; Lu Y; Pham P; Choong IC; VanderPorten EC; Bui M; Purkey HE; Evanchik MJ; Yang W
Bioorg Med Chem Lett; 2008 Oct; 18(20):5648-52. PubMed ID: 18793847
[TBL] [Abstract][Full Text] [Related]
16. The development of CNS-active LRRK2 inhibitors using property-directed optimisation.
Kavanagh ME; Doddareddy MR; Kassiou M
Bioorg Med Chem Lett; 2013 Jul; 23(13):3690-6. PubMed ID: 23721803
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel indolinone-based, potent, selective and brain penetrant inhibitors of LRRK2.
Troxler T; Greenidge P; Zimmermann K; Desrayaud S; Drückes P; Schweizer T; Stauffer D; Rovelli G; Shimshek DR
Bioorg Med Chem Lett; 2013 Jul; 23(14):4085-90. PubMed ID: 23768909
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological inhibition of LRRK2 cellular phosphorylation sites provides insight into LRRK2 biology.
Zhao J; Hermanson SB; Carlson CB; Riddle SM; Vogel KW; Bi K; Nichols RJ
Biochem Soc Trans; 2012 Oct; 40(5):1158-62. PubMed ID: 22988882
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of 3,6-diamino-1H-pyrazolo[3,4-b]pyridine derivatives as protein kinase inhibitors.
Chioua M; Samadi A; Soriano E; Lozach O; Meijer L; Marco-Contelles J
Bioorg Med Chem Lett; 2009 Aug; 19(16):4566-9. PubMed ID: 19615897
[TBL] [Abstract][Full Text] [Related]
20. Targeting LRRK2 in Parkinson's disease: an update on recent developments.
Chan SL; Tan EK
Expert Opin Ther Targets; 2017 Jun; 21(6):601-610. PubMed ID: 28443359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
